T3 Companies LLC Acquires New Shares in The Oncology Institute, Inc. $TOI

T3 Companies LLC acquired a new stake in The Oncology Institute, Inc. (NASDAQ:TOI) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 201,100 shares of the company’s stock, valued at approximately $716,000. Oncology Institute comprises 0.9% of T3 Companies LLC’s investment portfolio, making the stock its 22nd largest holding. T3 Companies LLC owned 0.20% of Oncology Institute at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Cetera Investment Advisers lifted its position in Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after acquiring an additional 4,545 shares during the last quarter. Pekin Hardy Strauss Inc. acquired a new position in Oncology Institute during the 4th quarter worth $36,000. State of Wyoming acquired a new position in Oncology Institute during the 2nd quarter worth $37,000. R Squared Ltd acquired a new position in Oncology Institute during the 4th quarter worth $41,000. Finally, Prelude Capital Management LLC acquired a new position in Oncology Institute during the 3rd quarter worth $41,000. Institutional investors and hedge funds own 36.86% of the company’s stock.

Insider Activity

In other news, insider Yale Podnos sold 23,451 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $5.38, for a total transaction of $126,166.38. Following the completion of the transaction, the insider owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. This represents a 8.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mohit Kaushal sold 57,286 shares of the company’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $3.50, for a total transaction of $200,501.00. Following the transaction, the director directly owned 211,016 shares of the company’s stock, valued at $738,556. This represents a 21.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders purchased 649,485 shares of company stock valued at $2,095,896 and sold 119,170 shares valued at $461,183. 8.50% of the stock is owned by company insiders.

Oncology Institute Stock Performance

Shares of TOI opened at $4.68 on Thursday. The company has a 50-day simple moving average of $3.90 and a 200-day simple moving average of $3.42. The firm has a market capitalization of $462.57 million, a P/E ratio of -12.65 and a beta of 0.37. The Oncology Institute, Inc. has a 52 week low of $2.02 and a 52 week high of $5.57.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.05. The company had revenue of $147.44 million for the quarter, compared to analyst estimates of $142.10 million. As a group, equities analysts forecast that The Oncology Institute, Inc. will post -0.17 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TOI has been the subject of a number of research analyst reports. BTIG Research boosted their target price on shares of Oncology Institute from $7.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday. Needham & Company LLC reissued a “buy” rating and set a $5.00 target price on shares of Oncology Institute in a research report on Monday, March 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a research report on Monday, April 20th. Finally, B. Riley Financial boosted their target price on shares of Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.